CN1310641C - Method and apparatus for releasing L-ascorbic acid to derma cortex - Google Patents
Method and apparatus for releasing L-ascorbic acid to derma cortex Download PDFInfo
- Publication number
- CN1310641C CN1310641C CNB011178132A CN01117813A CN1310641C CN 1310641 C CN1310641 C CN 1310641C CN B011178132 A CNB011178132 A CN B011178132A CN 01117813 A CN01117813 A CN 01117813A CN 1310641 C CN1310641 C CN 1310641C
- Authority
- CN
- China
- Prior art keywords
- ascorbic acid
- skin
- hydrophilic
- hygroscopicity
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a method and a composition for treating and preventing actinic skin aging or relevant skin diseases in a partial skin coating mode, which relates to a method of releasing L-ascorbic acid, L-ascorbic acid derivatives and/or extract containing the L-ascorbic acid to the dermis layer of the skin. The present invention also relates to a composition containing about 1% to 20% of L-ascorbic acid, L-ascorbic acid derivatives and/or extract containing the L-ascorbic acid, which is coated on a pharmacy-acceptable carrier having hygroscopic, hydrophilic and water-soluble liquid.
Description
The present invention relates to discharge L-ascorbic acid (vitamin C), L-ascorbic acid derivates and/or contain the method and the compositions thereof of L-ascorbic acid extract to dermal layer of the skin.And, said composition can by the part be applied to be used for the treatment of on the skin and/or prevent that light skin aging or relevant dermatosis such as tanned, wrinkle, color of the leather are bad, dyschromasia etc.
In the past, the L-ascorbic acid all was known to the useful effect of the blood flow of dermal layer of the skin with to the effect that collagen or elasticin (elastin) produce.So relevant nearest document of the present invention is listed below." with the regulation of L-ascorbic acid biosynthesis collagen " YaleJ.Biol.Med.58:554-559 (1985) of S.R.Pinnell.
" synthetic I type of the human skin fibroblast external biological of aged donor and III Collagen Type VI " Mechanism of Aging and Development of people such as Dumas, vol.73 (1994) pp.179-187.
" the L-ascorbic acid is for human skin fibroblast propagation and the collagen synthetic effect relevant with donor age " Journal of In vestigative Dermatology of people such as Phillips, vol.103, No.2, Aug.1994, pp.228-232.
" generation of elastic force scleroprotein and the minimizing that causes with age growth in the human skin fibroblast cultivation " Journal of In vestigative Dermatology of people such as Sephel, vol.86, No.3, Mar.1986, pp.279-285.
" character of the elastic force scleroprotein of people's face skin and the change of age of thickness " BritishJournal of Dermatologu of people such as Takema, Vol.131,1994, pp.641-648.
To the biggest obstacle of the therapeutic use of L-ascorbic acid is in order to bring into play above-mentioned useful effect, and actual needs discharges the very L-ascorbic acid of high concentration to skin corium.We thrust microelectrode to skin corium, by measuring oxidation-reduction potential, have proved under the oral administration situation of L-ascorbic acid, and the L-ascorbic acid concentrations in the skin corium does not almost increase.If in the medium of supporting L-ascorbic acid immigration dermal layer of the skin, add the L-ascorbic acid, another probability to the local skin coating is arranged.The system or the prescription (composition) of many relevant L-ascorbic acid topicals have been described in patent documentation.
These patent documentations comprise: the document of putting down in writing in US4938969 (Schinitsky), US5140043 (Darr), US5281196 (Sultenfuss), US5801192 (Dumas), US5843411 (Hernandez), US5853741 and these documents.
These prescriptions pointed out this prescription actual in skin corium release L-ascorbic acid to the test of the effect of fine wrinkle in the past.In these tests, do not have directly to measure the L-ascorbic acid concentrations in the skin corium, observed result might be various according to what contain in the tested composition, and many sometimes other compositions bring.
Therefore, the objective of the invention is method for releasing and compositions that (with the method that can prove) provides the dermal osmosis of support to the people (but avoiding stimulating) L-ascorbic acid, L-ascorbic acid derivates and/or contain L-ascorbic acid extract.
Another object of the present invention provides and reduces owing to too expose to the open air in sunray or L-ascorbic acid, the L-ascorbic acid derivates of the creasy surface that nature age propagation process causes and/or contain the method for releasing and the compositions thereof of L-ascorbic acid extract.
In order to reach purpose of the present invention, the method for releasing of the 1st invention of the present invention is to discharge L-ascorbic acid, L-ascorbic acid derivates and/or contain the method for L-ascorbic acid extract to dermis of skin, it is characterized in that being coated in L-ascorbic acid, L-ascorbic acid derivates that contains the 1%-that has an appointment about 20% in the pharmaceutically suitable carrier that comprises hygroscopicity, hydrophilic and water miscible liquid and/or the compositions that contains L-ascorbic acid extract.
In addition, the invention of the 2nd invention of the present invention such as above-mentioned the 1st record is characterized in that, as above-mentioned hygroscopicity, hydrophilic and water miscible liquid, uses the polyhydric alcohol with 3-4 hydroxyl and 3-10 carbon atom.
The invention of the 3rd invention of the present invention such as above-mentioned the 1st record is characterized in that, as above-mentioned hygroscopicity, hydrophilic and water miscible liquid, uses the mixture of carrier more than 2 kinds.
The 4th inventive compositions of the present invention, it is characterized in that, comprise hygroscopicity, hydrophilic and water-soluble liquid on pharmaceutics in the admissible carrier, contain L-ascorbic acid, the L-ascorbic acid derivates of the 1%-that has an appointment about 20% and/or contain the compositions of L-ascorbic acid extract.
The 5th invention of the present invention is characterized in that as the invention of the 4th record, and above-mentioned hygroscopicity, hydrophilic and water miscible liquid are the ethylene represented with following general formula and the linear polymer of propylene oxide.
RO-[CH
2CH(CH
3)O]
n-[CH
2CH
2O]
m-H
In this general formula, R is hydrogen or the alkyl with 1-18 carbon atom, 1≤n+m≤40.
The 6th invention of the present invention is characterized in that as the invention of the 4th record, is the mixture of carrier more than 2 kinds as above-mentioned hygroscopicity, hydrophilic and water miscible liquid.
The present invention is based on such discovery, if promptly polarity is maximum and for hygroscopic molecular weight is the L-ascorbic acid that organic solvent below 2000 can dissolve appropriate amount, is suitable as the L-ascorbic acid through the epithelium carrier so.Example to appropriate carrier is unqualified.Below enumerate this carrier.
1. general formula R O-[CH
2CH (CH
3) O]
n-[CH
2CH
2O]
mThe ethylene that-H represents and the linear polymer of propylene oxide ... formula (1).
In this formula, R is hydrogen or the alkyl with 1-18 carbon atom, 1≤n+m≤40.As the instantiation of this compounds, can select propylene glycol, dipropylene glycol, three contract four propylene glycol, polyethers (1 and 2 hydroxyls).
2. have the ethylene linear polymer of above-mentioned general formula and the mixture of propylene oxide.As the instantiation of this compounds, be have mean molecule quantity be 1000 (in above-mentioned general formula, R=H, the mixture of polypropylene glycol m=0) promptly contains the Acclaim of Lyondell company
TM(below
TMBe trade (brand) name) and mean molecule quantity be 270 (R=butyl in the above-mentioned general formula, n=m) poly-(oxyalkylene) copolymer, i.e. UCON of Union Carbide company
TM50-HB-55.
3. the polyhydric alcohol that has 3-4 hydroxyl and 3-10 carbon atom.
As the instantiation of this compounds, be glycerol.
Use the effect of following voltammeter commercial measurement carrier matrix.
Ultra micro small electrode (anode) and 2 ultra micro small electrodes of another electrode (reference electrode, negative electrode) of employing being thrust the platinum filament formation of 5 μ m in the glass carefully laterally thrust under the skin of shoulder or upper breast, so that make electrode top section reach skin corium.Distance between the top of two electrodes is maintained at about 1mm.In addition, above-mentioned ultra micro small electrode is documented in " Voltammetry at Ultrmicrodes Electrodes " in ElectroanalyticalChemistry of following document R.Mark Wightman and David O.Wipf, Vol 15, (Allan J.Bard among the pp.267-353, Marcel Dekker publishes, and 1989).
Reference test
25 periodic wave curves between (comparing with standard calomel electrode) makes-0.2～+ 0.2 volt according to the periodic wave frequency of 550 volts of per seconds, the integrated value of the anodic cycle ripple part of recording voltage-current curve is stored in the computer.The meansigma methods of these 25 periodic waves manifests the background value of the linear module at place as oxidation in the anodic cycle ripple.
The infiltration degree:
To in tested carrier base, contain the solution of 3%L-ascorbic acid with 0.05ml/cm
2Be coated on parts of skin (the total about 5cm of spreading area on the electrode
2), cause above-mentioned periodic wave after 20 seconds, measure the linear module that total oxidation manifests the place.The difference of this value and the oxidation background value that obtains in reference test is as the oxidation linear module of L-ascorbic acid.Be that it is the linear module of L-ascorbic acid concentrations (permeability) in the corium.
These values that obtain can not simply be interpreted as the real concentration of L-ascorbic acid, and the precision of mensuration is so high (± 10%) not.
In order to make in the body the real concentration of measured value and L-ascorbic acid relevant to a certain extent, same electrode is immersed among the human blood 0.5ml that remains on 37 ℃, carry out amperometric determination as above-mentioned, in this blood sample, add L-ascorbic acid (adding 7.5mg in the 1ml blood), carry out amperometric determination again.Make the difference of these 2 oxidation numbers at random be amplified to 100 times of expressions.The results are shown in Table 1 with several mensuration that this yardstick is implemented.The L-ascorbic acid directly is dissolved in the carrier solvent, and for the accelerate dissolution process, heating as required prepares sample in the table.
[table 1]
Oxidation number when the treatment of coating L-ascorbic acid is formed with prescription in skin volume
| Carrier matrix | The % of L-ascorbic acid | Oxidation number |
| Propylene glycol | 0 | 0 |
| Propylene glycol | 3 | 50 |
| Glycerol | 0 | 0 |
| Glycerol | 3 | 20 |
| Three four propylene glycol that contract | 0 | 0 |
| Three four propylene glycol that contract | 3 | 40 |
| Propylene glycol 400 1 | 0 | 0 |
| Propylene glycol 400 1 | 3 | 15 |
| Acclaim TM1000 2 | 0 | 0 |
| Acclaim TM1000 2 | 3 | 10 |
| UCON TM50-HB-55 3 | 0 | 0 |
| UCON TM50-HB-55 3 | 3 | 60 |
| UCON TM50-HB-100 4 | 0 | 0 |
| UCON TM50-HB-100 4 | 3 | 25 |
| UCON TM50-HB-2000 5 | 0 | 0 |
| UCON TM50-HB-2000 5 | 3 | 20 |
| UCON TM50-LB-65 6 | 0 | 0 |
| UCON TM50-LB-65 6 | 3 | 20 |
In table 1, polypropylene glycol 400
1Be to be the mixture of 400 polypropylene glycol from the derive mean molecule quantity that obtains of the polymerization of propylene oxide.
Acclaim
TM1000
2Be to be the mixture (supplier is a Lyondell company) of 1000 polypropylene glycol from the derive mean molecule quantity that obtains of the polymerization of propylene oxide.
UCON
TM50-HB-55
3Be in the formula (1) of page 3 record, (the R=butyl, in the time of n=m) and mean molecule quantity be 270 polyether mixture (supplier Union Carbide company).
UCON
TM50-HB-100
4Be in formula (1), (the R=butyl, in the time of n=m) and mean molecule quantity be 520 polyether mixture (supplier Union Carbide company).
UCON
TM50-HB-2000
5Be in formula (1), (the R=butyl, in the time of n=m) and mean molecule quantity be 2660 polyether mixture (supplier Union Carbide company).
UCON
TM50-LB-65
6Be in formula (1), (the R=butyl, in the time of n=0) and mean molecule quantity be 340 polyether mixture (supplier Union Carbide company).
For ascorbyl palmitate, proved also that with same procedure the part by the solution that uses the hygroscopicity carrier is coated with the transepithelial impregnability that produces.
In addition, method of the present invention and compositions thereof, in the amount of the L-ascorbic acid that on pharmaceutics, contains in the admissible carrier, L-ascorbic acid derivates and/or the L-ascorbic acid that comprise hygroscopicity, hydrophilic and water-soluble liquid scope at 1%-20%, can obtain desired action effect, 3%-10% is optimal.
The present invention can emit L-ascorbic acid, L-ascorbic acid derivates and/or contain the extract of L-ascorbic acid to dermal layer of the skin, comprising in the carrier that on pharmaceutics, allows of hygroscopicity, hydrophilic and water-soluble liquid, containing L-ascorbic acid, the L-ascorbic acid derivates of effective dose and/or contain the extract of L-ascorbic acid.Its hygroscopicity substrate makes the L-ascorbic acid by the skin epithelium, reasonably becomes possibility to the skin corium diffusion continuously.Such composition can be used for the treatment of and/or prevent light skin aging or relevant dermatosis by to local skin coating, and for example tanned, wrinkle, color of the leather are bad, dyschromasia etc.
Claims (4)
1. one kind is used for discharging the L-ascorbic acid composition to dermal layer of the skin, it is characterized in that: by general formula R O-[CH
2CH (CH
3) O]
n-[CH
2CH
2O]
mThe L-ascorbic acid that contains 1%-20% in the hygroscopicity that-H represents, hydrophilic and the water miscible pharmaceutically acceptable liquid-carrier, in described general formula, R is hydrogen or the alkyl with 1-18 carbon atom, 1≤n+m≤40; And said composition is neither moisture, does not also contain DIMETHYLISOSORBIDE.
2. the compositions of claim 1, it is characterized in that: described hygroscopicity, hydrophilic and water miscible liquid are the mixture of carrier more than 2 kinds.
3. the compositions of claim 1, it is characterized in that: described hygroscopicity, hydrophilic and water miscible liquid are propylene glycol.
4. the compositions of claim 1 is characterized in that: described hygroscopicity, hydrophilic and water miscible liquid are that mean molecule quantity that described general formula is represented when R is butyl, n=m is 270 polyether mixture, and the trade name of this polyether mixture is UCON
TM-50-HB-55
3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011178132A CN1310641C (en) | 2001-03-23 | 2001-03-23 | Method and apparatus for releasing L-ascorbic acid to derma cortex |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011178132A CN1310641C (en) | 2001-03-23 | 2001-03-23 | Method and apparatus for releasing L-ascorbic acid to derma cortex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1376465A CN1376465A (en) | 2002-10-30 |
| CN1310641C true CN1310641C (en) | 2007-04-18 |
Family
ID=4662878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011178132A Expired - Fee Related CN1310641C (en) | 2001-03-23 | 2001-03-23 | Method and apparatus for releasing L-ascorbic acid to derma cortex |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1310641C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1223567A (en) * | 1996-06-28 | 1999-07-21 | 尤尼利弗公司 | Vitamin C delivery system |
-
2001
- 2001-03-23 CN CNB011178132A patent/CN1310641C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1223567A (en) * | 1996-06-28 | 1999-07-21 | 尤尼利弗公司 | Vitamin C delivery system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1376465A (en) | 2002-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7189341B2 (en) | Electrochemical sensor ink compositions, electrodes, and uses thereof | |
| EP0601720B1 (en) | Techniques to improve the performance of electrochemical sensors | |
| JPH07503989A (en) | Acrylic copolymer membranes for biosensors | |
| Wilson et al. | Significant Differences in the Electrochemical Behavior of the α-, β-, γ-, and δ-Tocopherols (Vitamin E) | |
| CN101925613B (en) | Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics | |
| CN113416344B (en) | Photo-crosslinking phospholipid double-layer membrane for nanopore gene sequencing and preparation method thereof | |
| Uchiyama et al. | Biocompatible polymer alloy membrane for implantable artificial pancreas | |
| WO2016025064A1 (en) | Temperature insensitive in vivo analyte devices, methods and systems | |
| CN1310641C (en) | Method and apparatus for releasing L-ascorbic acid to derma cortex | |
| CN108700541A (en) | Electrochemical sensor and painting method, manufacturing method and corresponding purposes | |
| KR20180006835A (en) | Bio sensor and manufacturing method thereof | |
| CN113447544A (en) | Degradable transient NO sensor and preparation method thereof | |
| Ha et al. | A dual electrochemical microsensor for simultaneous imaging of oxygen and pH over the rat kidney surface | |
| Griffin et al. | Increased factor XIIIa transglutaminase expression indermal dendrocytes after treatment with α-hydroxy acids: potential physiologic significance | |
| EP3777683A1 (en) | Sensor using phenazine derivative or high molecular weight redox polymer containing phenazine derivative | |
| EP2333544A1 (en) | Sterilisable chemistry for test elements | |
| El-Maali | Voltammetric analysis of ceftazidime after preconcentration at various mercury and carbon electrodes: application to sub-ppb level determination in urine samples | |
| CN1375290A (en) | Method for releasing L-asorbic substance to dermis layer of skin and composition thereof | |
| JP5106715B2 (en) | Composition for use in a method for releasing L-ascorbic acid, an L-ascorbic acid derivative to the dermal layer of the skin | |
| Xian et al. | Preparation of microporous aluminium anodic oxide film modified Pt nano array electrode and application in direct measurement of nitric oxide release from myocardial cells | |
| Compañ et al. | Oxygen transport through methacrylate-based hydrogels with potential biological capability | |
| KR100864350B1 (en) | System for delivery of l-ascorbic acid, derivatives of l-ascorbic acid/or extracts containing l-ascorbic acid to the dermis layer of the skin | |
| Şengün et al. | Analytical investigations of cephalosporins. Part 9. Polarographic behaviour of some selected cephalosporins and assay of their formulations | |
| CN111925467A (en) | Application of zwitterion or zwitterion polymer as pH buffering material | |
| US20230355144A1 (en) | Highly porous, bioresorbable electrospun sensors for optical detection of tissue oxygenation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070418 Termination date: 20160323 |